CN116333049B - Atypical hydrophobic amino acid-based self-assembled short peptide and application thereof - Google Patents
Atypical hydrophobic amino acid-based self-assembled short peptide and application thereof Download PDFInfo
- Publication number
- CN116333049B CN116333049B CN202310186188.2A CN202310186188A CN116333049B CN 116333049 B CN116333049 B CN 116333049B CN 202310186188 A CN202310186188 A CN 202310186188A CN 116333049 B CN116333049 B CN 116333049B
- Authority
- CN
- China
- Prior art keywords
- short peptide
- hydrophobic drug
- hydrophobic
- doxorubicin
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 139
- 230000002209 hydrophobic effect Effects 0.000 title claims abstract description 77
- 150000001413 amino acids Chemical class 0.000 title abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 75
- 229940079593 drug Drugs 0.000 claims abstract description 68
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 239000002077 nanosphere Substances 0.000 claims abstract description 20
- 239000003937 drug carrier Substances 0.000 claims abstract description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 60
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 44
- 229930012538 Paclitaxel Natural products 0.000 claims description 42
- 229960001592 paclitaxel Drugs 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 33
- 229960004679 doxorubicin Drugs 0.000 claims description 30
- 238000009472 formulation Methods 0.000 claims description 24
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 claims description 21
- 229960004134 propofol Drugs 0.000 claims description 20
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 claims description 20
- 238000001338 self-assembly Methods 0.000 claims description 20
- 229960001690 etomidate Drugs 0.000 claims description 19
- 239000002539 nanocarrier Substances 0.000 claims description 12
- -1 simoxicillin Chemical compound 0.000 claims description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 8
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 8
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 8
- 229960002390 flurbiprofen Drugs 0.000 claims description 8
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 8
- 229960000311 ritonavir Drugs 0.000 claims description 8
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 8
- KPBZROQVTHLCDU-UHFFFAOYSA-N clevidipine Chemical compound CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl KPBZROQVTHLCDU-UHFFFAOYSA-N 0.000 claims description 7
- 229960003621 clevidipine butyrate Drugs 0.000 claims description 7
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 6
- 238000007385 chemical modification Methods 0.000 claims description 6
- 238000002372 labelling Methods 0.000 claims description 6
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 6
- 229960002855 simvastatin Drugs 0.000 claims description 6
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 4
- NYKRSGJRIJJRRK-UHFFFAOYSA-N 1-chloro-2-(2-chlorophenyl)sulfonylbenzene Chemical compound ClC1=CC=CC=C1S(=O)(=O)C1=CC=CC=C1Cl NYKRSGJRIJJRRK-UHFFFAOYSA-N 0.000 claims description 4
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 4
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 4
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 claims description 4
- 108010019625 Atazanavir Sulfate Proteins 0.000 claims description 4
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 4
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 4
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 4
- 241000158621 Brucea Species 0.000 claims description 4
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 4
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 4
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 4
- 108010036949 Cyclosporine Proteins 0.000 claims description 4
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 claims description 4
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 claims description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 4
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 claims description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 4
- 102000004877 Insulin Human genes 0.000 claims description 4
- 108090001061 Insulin Proteins 0.000 claims description 4
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 4
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 4
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 4
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 claims description 4
- 229930193140 Neomycin Natural products 0.000 claims description 4
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 4
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 4
- 229930003316 Vitamin D Natural products 0.000 claims description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- 229930003448 Vitamin K Natural products 0.000 claims description 4
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 claims description 4
- 229960001997 adefovir Drugs 0.000 claims description 4
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
- 229960005260 amiodarone Drugs 0.000 claims description 4
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 claims description 4
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 4
- 229960003942 amphotericin b Drugs 0.000 claims description 4
- 229960003277 atazanavir Drugs 0.000 claims description 4
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 claims description 4
- 229960005370 atorvastatin Drugs 0.000 claims description 4
- 229960004099 azithromycin Drugs 0.000 claims description 4
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 4
- 229960002092 busulfan Drugs 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 4
- 229940127093 camptothecin Drugs 0.000 claims description 4
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 4
- 229960000623 carbamazepine Drugs 0.000 claims description 4
- 229960004195 carvedilol Drugs 0.000 claims description 4
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 claims description 4
- 229960000590 celecoxib Drugs 0.000 claims description 4
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 4
- 229960003677 chloroquine Drugs 0.000 claims description 4
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 4
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 4
- 229960001076 chlorpromazine Drugs 0.000 claims description 4
- 229960001265 ciclosporin Drugs 0.000 claims description 4
- 229960005132 cisapride Drugs 0.000 claims description 4
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 claims description 4
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- 229940109262 curcumin Drugs 0.000 claims description 4
- 235000012754 curcumin Nutrition 0.000 claims description 4
- 239000004148 curcumin Substances 0.000 claims description 4
- 229930182912 cyclosporin Natural products 0.000 claims description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 4
- 229960000975 daunorubicin Drugs 0.000 claims description 4
- 229960003957 dexamethasone Drugs 0.000 claims description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 4
- 229960003529 diazepam Drugs 0.000 claims description 4
- 229960001259 diclofenac Drugs 0.000 claims description 4
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 4
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 4
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- 229960003804 efavirenz Drugs 0.000 claims description 4
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims description 4
- 229960005309 estradiol Drugs 0.000 claims description 4
- 229930182833 estradiol Natural products 0.000 claims description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 4
- 229960005420 etoposide Drugs 0.000 claims description 4
- 229960002949 fluorouracil Drugs 0.000 claims description 4
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 229960002867 griseofulvin Drugs 0.000 claims description 4
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 claims description 4
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 4
- 229960004171 hydroxychloroquine Drugs 0.000 claims description 4
- 229960001680 ibuprofen Drugs 0.000 claims description 4
- 229960000905 indomethacin Drugs 0.000 claims description 4
- 229940125396 insulin Drugs 0.000 claims description 4
- 229960004525 lopinavir Drugs 0.000 claims description 4
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 4
- 229960004844 lovastatin Drugs 0.000 claims description 4
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 4
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 claims description 4
- 229960001810 meprednisone Drugs 0.000 claims description 4
- 229960000485 methotrexate Drugs 0.000 claims description 4
- 229960004023 minocycline Drugs 0.000 claims description 4
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 claims description 4
- 229960002009 naproxen Drugs 0.000 claims description 4
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 4
- 229960000884 nelfinavir Drugs 0.000 claims description 4
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 4
- 229960004927 neomycin Drugs 0.000 claims description 4
- 229940060184 oil ingredients Drugs 0.000 claims description 4
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 4
- 229960002702 piroxicam Drugs 0.000 claims description 4
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 4
- 229960004622 raloxifene Drugs 0.000 claims description 4
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 4
- 229930002330 retinoic acid Natural products 0.000 claims description 4
- 229960002930 sirolimus Drugs 0.000 claims description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 4
- 229960003787 sorafenib Drugs 0.000 claims description 4
- 229960001967 tacrolimus Drugs 0.000 claims description 4
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 4
- 229960001603 tamoxifen Drugs 0.000 claims description 4
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 4
- 229960001278 teniposide Drugs 0.000 claims description 4
- 229960000351 terfenadine Drugs 0.000 claims description 4
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims description 4
- 229960001727 tretinoin Drugs 0.000 claims description 4
- 229960004528 vincristine Drugs 0.000 claims description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 235000019155 vitamin A Nutrition 0.000 claims description 4
- 239000011719 vitamin A Substances 0.000 claims description 4
- 235000019166 vitamin D Nutrition 0.000 claims description 4
- 239000011710 vitamin D Substances 0.000 claims description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- 235000019168 vitamin K Nutrition 0.000 claims description 4
- 239000011712 vitamin K Substances 0.000 claims description 4
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 4
- 229940045997 vitamin a Drugs 0.000 claims description 4
- 229940046008 vitamin d Drugs 0.000 claims description 4
- 229940046010 vitamin k Drugs 0.000 claims description 4
- 108010038807 Oligopeptides Proteins 0.000 claims description 3
- 102000015636 Oligopeptides Human genes 0.000 claims description 3
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 2
- 229930188522 aclacinomycin Natural products 0.000 claims description 2
- 229960004176 aclarubicin Drugs 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 229940059260 amidate Drugs 0.000 claims description 2
- 230000009435 amidation Effects 0.000 claims description 2
- 238000007112 amidation reaction Methods 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960002965 pravastatin Drugs 0.000 claims description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 claims description 2
- 230000021736 acetylation Effects 0.000 claims 2
- 238000006640 acetylation reaction Methods 0.000 claims 2
- 229960004742 raltegravir Drugs 0.000 claims 1
- CZFFBEXEKNGXKS-UHFFFAOYSA-N raltegravir Chemical compound O1C(C)=NN=C1C(=O)NC(C)(C)C1=NC(C(=O)NCC=2C=CC(F)=CC=2)=C(O)C(=O)N1C CZFFBEXEKNGXKS-UHFFFAOYSA-N 0.000 claims 1
- 239000002245 particle Substances 0.000 abstract description 9
- 230000000857 drug effect Effects 0.000 abstract description 4
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 2
- 230000003013 cytotoxicity Effects 0.000 abstract description 2
- 238000005232 molecular self-assembly Methods 0.000 abstract 1
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 50
- 102000004196 processed proteins & peptides Human genes 0.000 description 40
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 25
- 238000011068 loading method Methods 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 23
- 229940024606 amino acid Drugs 0.000 description 23
- 241000700159 Rattus Species 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 239000010413 mother solution Substances 0.000 description 17
- 239000000725 suspension Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000012452 mother liquor Substances 0.000 description 14
- 150000002632 lipids Chemical class 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 238000003760 magnetic stirring Methods 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 238000009210 therapy by ultrasound Methods 0.000 description 11
- 206010033128 Ovarian cancer Diseases 0.000 description 10
- 206010061535 Ovarian neoplasm Diseases 0.000 description 10
- 239000002105 nanoparticle Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000002189 fluorescence spectrum Methods 0.000 description 9
- 238000003917 TEM image Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241000322338 Loeseliastrum Species 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 239000002960 lipid emulsion Substances 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- 206010039897 Sedation Diseases 0.000 description 4
- 230000003444 anaesthetic effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 230000036280 sedation Effects 0.000 description 4
- 239000012192 staining solution Substances 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011033 desalting Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 238000002173 high-resolution transmission electron microscopy Methods 0.000 description 3
- 125000001165 hydrophobic group Chemical group 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001624 sedative effect Effects 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 2
- 241001535291 Analges Species 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 206010063181 Propofol infusion syndrome Diseases 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 229960000711 alprostadil Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000009194 climbing Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000035322 succinylation Effects 0.000 description 2
- 238000010613 succinylation reaction Methods 0.000 description 2
- 230000033912 thigmotaxis Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GXGJIOMUZAGVEH-UHFFFAOYSA-N Chamazulene Chemical group CCC1=CC=C(C)C2=CC=C(C)C2=C1 GXGJIOMUZAGVEH-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940028652 abraxane Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000006480 benzoylation reaction Methods 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229960004969 dalteparin Drugs 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000007037 hydroformylation reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920001428 methoxy poly(ethylene glycol)-block-poly(l-lactic acid) Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002121 nanofiber Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 231100000512 nanotoxicity Toxicity 0.000 description 1
- 239000002071 nanotube Substances 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention provides a self-assembled short peptide based on atypical hydrophobic amino acid and application thereof, belonging to the field of drug carriers. The amino acid sequence of the short peptide is shown as SEQ ID NO. 1. The short peptide can load a plurality of hydrophobic drugs through a molecular self-assembly mechanism to form nanospheres with uniform particle sizes, so that the drugs can be effectively transported into cells or tissues to exert the drug effect, the short peptide is safe and has no obvious cytotoxicity, the preparation process is simple, and the short peptide is a carrier of the hydrophobic drugs with great development prospect.
Description
The present application is a divisional application filed on the invention patent application with the application number of 202010638716.X and the application date of 2020, 07 and 03.
Technical Field
The invention belongs to the field of drug carriers, and in particular relates to a self-assembled short peptide based on atypical hydrophobic amino acid and application of the self-assembled short peptide as a hydrophobic drug carrier.
Background
In the current drug development, many potential small molecule drugs are hydrophobic substances and have poor water solubility, and the preparation generally needs to be dispersed and dissolved in aqueous solution or aqueous solution by using a carrier to be administered by injection. The hydrophobic drug carriers widely used in clinic at present mainly comprise materials such as lipid and the like. Taking the most commonly used anticancer drug taxol as an example, the drugs are marketedTaxol injection Taxol contains about 527mg/mL polyoxyethylene castor oil and 49.7% absolute ethyl alcohol as solvent; the most commonly used general anesthetic drugs such as propofol are fat emulsion preparations taking lipid molecules such as natural soybean oil, egg yolk lecithin and the like as carriers; the vasodilator adopts lipid molecules such as soybean oil, lecithin, oleic acid and the like as a carrier of fat emulsion injection; the antihypertensive drug clevidipine butyrate also contains injectable oil and phospholipid components. However, there are still problems with the clinical use of lipid components such as poor stability (Anesth Analg 2003, 97:769-771), causing pain for injection (Acta Anaesthesiol Scand 2001, 45:839-841), inducing hyperlipidemia (Lancet 2001, 357:606-607), and susceptibility to infection by rapid bacterial growth (Anesth Analg 1999, 88:209-212). The Taxol injection Taxol also has more adverse reactions in the clinical use process, such as acute hypersensitivity (Allergy Asthma Immunol Res 2016, 8:174-177), neurotoxicity (Nanomedicine 2015, 11:1925-1938) and the like; the problem of propofol fat emulsion injection with propofol infusion syndrome (propofol infusion syndrome, PRIS) (Crit Care 2015, 19:398); clevidipine butyrate injection limits the use of patients with severe lipid metabolism disorders (see clevidipine butyrate injection instructions), and so on. The above problems are essentially all related to lipid components. Therefore, it is very promising to develop hydrophobic drug carrier materials that do not contain lipid components.
Currently, some non-lipid materials have been applied in clinic, such as a preparation Abraxane of human serum albumin-entrapped paclitaxel, which has been marketed in the United states in 2005, and has small side effects, short administration time and reduced adverse reactions (Int J Nanomedicine 2009, 4:99-105). However, this dosage form is limited by the human blood source of the albumin carrier and the corresponding risk of microbial and viral contamination, which is expensive. Paclitaxel formulations Cynviloq have been marketed in korea in 2007 (Adv Drug Deliver Rev 2017,122: 20-30) using polymer mPEG-PLLA materials, but polymer materials are expensive, synthesis processes are complicated, and polymer nanotoxicity still needs to be continued. In terms of biosafety, the artificially synthesized short peptide has unique advantages and is a very potential drug carrier material. For example, chinese patent No. 00105625.5 (ZL patent No. CN1148227C entitled "therapeutic compound and use thereof") discloses a therapeutic compound based on a short peptide carrier and use thereof. However, the invention is to form therapeutic compounds by chemical combination of paclitaxel, glutamic acid and aspartic acid, rather than directly load the drug by nanoparticles formed by self-assembly of short peptides.
Artificially designed self-assembled short peptides are receiving increasing attention as a material of the type which is internationally emerging in recent years (Nano Today 2016, 11:41-60). The polypeptide is a kind of short peptide molecules which are artificially designed and synthesized and are composed of natural amino acids, and can self-assemble in aqueous solution to form structures such as nanotubes, nanofibers, nanovesicles or nanoparticles. Because the components of the self-assembled short peptide are short peptides, degradation products are natural L-type amino acids, and the self-assembled short peptide has good biocompatibility and safety. The artificial design and synthesis mode can make the sources of the materials clear, the quality is controllable, and the functional modification is convenient.
However, existing self-assembled short peptides have their own disadvantages when used as hydrophobic drug carriers. The self-assembled short peptides for loading hydrophobic drugs are reported in the prior art in two major types, namely, a lamellar structure with a hydrophobic surface is formed to wrap drug particles, and the obtained drug-short peptide complex is mostly irregular micron-sized particles, and has poor uniformity and stability (Int J Nanomed 2011, 6:2143-2153); the other forms nano-scale micelle with compact hydrophobic inner core to load medicine, and has even particle size and better dispersivity, but very limited medicine loading capacity (Int J Nanomed 2015, 10:847-858).
The self-assembled short peptide reported in the literature has lower drug loading rate, poor preparation stability and significantly inferior drug loading capacity compared with most of natural lipid molecules, and the problems are the main reasons that the self-assembled short peptide carrier has not been popularized at present. In order to develop a self-assembled oligopeptide hydrophobic drug carrier with conversion value, the drug loading capacity of the self-assembled oligopeptide hydrophobic drug carrier needs to be improved as much as possible while ensuring the formation of uniform and stable drug loading nanoparticles.
The existing self-assembled short peptide contains a large amount of hydrophobic amino acids to drive the self-assembly and realize the loading of the hydrophobic drugs, and the existence of the large amount of hydrophobic amino acids leads to the limited water solubility of the short peptide, and is easy to aggregate and precipitate under high concentration. The solubility of the short peptide material itself and the loading capacity of the material to hydrophobic drugs appear to be a group of irreconcilable contradictions, greatly limiting the application of self-assembled short peptides as hydrophobic drug carriers.
Disclosure of Invention
The invention aims to provide a novel self-assembled short peptide based on atypical hydrophobic amino acid, which has a drug carrying effect comparable to that of a lipid carrier, and the technical scheme is as follows:
a short peptide has an amino acid sequence shown in SEQ ID NO. 1.
The short peptide as described above, wherein the N-terminal and/or C-terminal of the short peptide is chemically modified;
the N-terminal chemical modification is alternatively selected from: alkanoylation, biotin labeling, fatty acid modification, benzoylation, 2-aminobenzoylation, maleimide, haloalkylation, succinylation, dihydrazineimide, fluorescent group labeling;
the C-terminal chemical modification is alternatively selected from: amidation, esterification, hydroformylation, alcoholization, succinylation, and fluorescent group labeling.
The short peptide, wherein the fluorescent group chemically modified at the N-terminal is FAM, FITC or TAMRA;
the fluorescent group chemically modified at the C end is AMC, CMK and FMK.
The short peptide as described above, wherein the N-terminal is chemically modified to be acetylated; and/or, the C-terminus is chemically modified to amidate.
The use of the foregoing short peptides in the preparation of a hydrophobic drug carrier.
The use as described above, wherein the carrier is a nanosphere formed by self-assembly of the short peptide.
As in the case of the use described above, the hydrophobic drug is paclitaxel, doxorubicin, curcumin, docetaxel, vincristine, camptothecin, hydroxycamptothecin, etoposide, retinoic acid, fluorouracil, methotrexate, teniposide, daunorubicin, aclacin, sorafenib, methylprednisone, minocycline, cisplatin, atorvastatin, simvastatin, lovastatin, amiodarone, carbamazepine, carvedilol, chlorpromazine, cisapride, chlorophenylsulfone, azithromycin, neomycin, amphotericin B, griseofulvin, celecoxib, raloxifene, flurbiprofen, indomethacin, ibuprofen, tamoxifen, simoxicillin, simvastatin, and other drugs any one or a mixture of several of diclofenac, naproxen, piroxicam, ralteravir, efavirenz, nelfinavir, atazanavir, ritonavir, sirolimus, busulfan, tacrolimus, ta Lin Luoer, terfenadine, estradiol, vitamin A, vitamin D, vitamin E, vitamin K, propofol, etomidate, perfluorocarbon, diazepam, alprostadil, complex liposoluble vitamins, dexamethasone, flurbiprofen ester, clevidipine butyrate, brucea oil, cyclosporine, insulin, adefovir, chloroquine, hydroxychloroquine, fampicvir, lopinavir, ritonavir and the like.
The use as described above, wherein the hydrophobic drug is paclitaxel, doxorubicin, etomidate or propofol.
A hydrophobic drug carrier, which is a nanosphere formed by self-assembly of the aforementioned short peptides.
A nano-carrier preparation takes a hydrophobic drug as an active ingredient and takes nanospheres formed by self-assembly of the short peptides as carriers.
The content ratio of short peptide to hydrophobic drug in the aforementioned nanocarrier formulation was 5 μmol: 1-100 mg.
As in the case of the nanocarrier formulations described previously, the hydrophobic drug is paclitaxel, doxorubicin, curcumin, docetaxel, vincristine, camptothecin, hydroxycamptothecin, etoposide, retinoic acid, fluorouracil, methotrexate, teniposide, daunorubicin, aclacinomycin, sorafenib, cisplatin, methylprednisone, minocycline, atorvastatin, simvastatin, lovastatin, amiodarone, carbamazepine, carvedilol, chlorpromazine, cisapride, chlorophenylsulfone, azithromycin, neomycin, amphotericin B, griseofulvin, celecoxib, raloxifene, flurbiprofen, indomethacin, ibuprofen, tamoxifen, pravastatin, and other drugs any one or a mixture of several of diclofenac, naproxen, piroxicam, ralteravir, efavirenz, nelfinavir, atazanavir, ritonavir, sirolimus, busulfan, tacrolimus, ta Lin Luoer, terfenadine, estradiol, vitamin A, vitamin D, vitamin E, vitamin K, propofol, etomidate, perfluorocarbon, diazepam, alprostadil, complex liposoluble vitamins, dexamethasone, flurbiprofen ester, clevidipine butyrate, brucea oil, cyclosporine, insulin, adefovir, chloroquine, hydroxychloroquine, fampicvir, lopinavir, ritonavir and the like.
As in the previous nanocarrier formulations, the hydrophobic drug is paclitaxel, doxorubicin, etomidate, or propofol.
As the nano-carrier preparation, the hydrophobic drug is paclitaxel, and the content ratio of the short peptide to the hydrophobic drug is 1 mu mol:1mg;
or the hydrophobic drug is doxorubicin, and the content ratio of the short peptide to the hydrophobic drug is 1 mu mol:1mg;
or the hydrophobic drug is etomidate, and the content ratio of the short peptide to the hydrophobic drug is 5 mu mol:20mg;
or the hydrophobic drug is propofol, and the content ratio of the short peptide to the hydrophobic drug is 9.9 mu mol/100 mg.
Although three amino acids of glutamine (Q), tyrosine (Y) and threonine (T) are generally classified as polar amino acids (hydrophilic amino acids) in textbooks, they have certain hydrophobicity in theory because their side chains contain hydrophobic groups such as dimethylene, benzene ring and methyl, respectively, and can provide hydrophobic effects for self-assembly as an atypical hydrophobic amino acid. Meanwhile, the amide groups at the ends of the glutamine (Q) and asparagine (N) side chains can also form hydrogen bonds to promote self-assembly. On the other hand, the amino acid side chain groups of glutamine (Q), tyrosine (Y), threonine (T), asparagine (N), serine (S) and glycine (G) are uncharged, and thus do not generate electrostatic repulsion, which is also very favorable for self-assembly. The following table summarizes the characteristics of these amino acids that are not traditional hydrophobic amino acids, but may be advantageous for short peptide self-assembly to occur.
Unlike traditional self-assembled short peptide with typical hydrophobic amino acids (alanine (A), valine (V), leucine (L), isoleucine (I), phenylalanine (F), tryptophan (W), methionine (M) and proline (P)) as main components, the short peptide of the invention is self-assembled short peptide mainly composed of atypical hydrophobic amino acids Q, Y, T, and is a brand new design. Compared with the current short peptide carrier, the short peptide has obviously improved drug carrying capacity, and can have better dispersibility and stability in aqueous solution; the short peptide of the invention is used as a carrier of a hydrophobic drug to prepare a preparation, so that the drug effect can reach the level close to the existing lipid carrier drug preparation.
It should be apparent that, in light of the foregoing, various modifications, substitutions and alterations can be made herein without departing from the spirit and scope of the invention as defined by the appended claims.
The above-described aspects of the present invention will be described in further detail below with reference to specific embodiments in the form of examples. It should not be understood that the scope of the above subject matter of the present invention is limited to the following examples only. All techniques implemented based on the above description of the invention are within the scope of the invention.
Drawings
FIG. 1 is a TEM image of a nanosphere formed after loading of Q5Y (a), Q6TY (b) and Q7GY (c) with pyrene. Scale bar = 100nm.
FIG. 2 is a graph showing fluorescence spectra of Q5Y-loaded pyrene-forming nanoparticle suspensions within 14 days.
Fig. 3 is a TEM image of A5Y loaded with pyrene to form non-uniform nanoparticles. Scale bar = 100nm.
FIG. 4 is a graph showing fluorescence spectra of A5Y-loaded pyrene-forming nanoparticle suspensions within 14 days.
FIG. 5 is a graph showing the proliferation inhibition effect of Q5Y-loaded paclitaxel (Q5Y-PTX) on ovarian cancer cells skov 3.
FIG. 6 is a graph showing the proliferation inhibition effect of Q6 TY-loaded doxorubicin (Q6 TY-DOX) on ovarian cancer cells skov 3.
FIG. 7 is a graph showing the effect of Q5Y, Q TY and Q7GY on ovarian cancer cell skov 3.
Fig. 8 is a TEM image of Q5Y, Q TY and Q7GY loaded paclitaxel forming nanospheres.
Fig. 9 is a TEM image of doxorubicin loaded Q5Y, Q TY and Q7GY to form nanospheres.
Fig. 10 is a TEM image of Q7GY loaded etomidate forming nanospheres.
Fig. 11 is a TEM image of Q7GY loaded propofol forming nanospheres.
FIG. 12 is the fluorescence spectra of short peptides Q5Y, Q3TY2, Q4GY2, Q4NY2, Q5A2SG combined with thioflavin T, showing that they have similar self-assembly behavior.
FIG. 13 is a fluorescence spectrum of the short peptides N5Y, S5Y, D5Y, E5Y, K5Y, R5Y and H5Y combined with thioflavin T, showing that they do not have self-assembly behavior.
Fig. 14 is a TEM image of the short peptides Q3TY2, Q4GY2, Q4NY2, Q5A2SG loaded with the model hydrophobic drug pyrene forming nanospheres.
Detailed Description
Example 1: loading of the short peptides with the model hydrophobic Compound pyrene
The material comprises the following components: ac-Gln-Gln-Gln-Gln-Gln-Tyr-NH 2 Abbreviated as Q5Y, ac represents acetyl and is shown as SEQ ID NO.1 in the amino acid sequence table; ac-Thr-Gln-Gln-Gln-Gln-Gln-Gln-Tyr-NH 2 Abbreviated as Q6TY,SEQ ID NO.2 in the amino acid sequence table; ac-Gly-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Tyr-NH 2 Abbreviated as Q7GY, SEQ ID NO.3 in the amino acid sequence Listing, was delegated to the company Shandong Katsuwonshi Biotechnology Co.
Pyrene was purchased from Sigma-Aldrich.
Q5Y, Q6TY, Q7GY were each dissolved in water at 5mM, and sonicated for 5min. 20mg of pyrene is added into 10mL of short peptide mother liquor, and the mixture is placed at room temperature and magnetically stirred at 2000rpm/min for 4 hours, and then is subjected to ultrasonic treatment for 30 minutes, so that stable milky suspension is formed, and the suspension is placed at 4 ℃ for storage.
Morphological features were observed by high resolution transmission electron microscopy. After diluting the above suspension with water 5 times, 10. Mu.L of the sample solution was applied to a 400 mesh copper wire for 5 minutes, and then blotted with a piece of filter paper. Then, 10. Mu.L of 2% phosphotungstic acid was added thereto for dyeing for 3min. The final staining solution was blotted with filter paper and dried. And then imaging by adopting a transmission electron microscope.
The suspension of the above Q5Y-loaded pyrene was allowed to stand at room temperature, 50. Mu.L of the suspension was taken out from the top layer on days 0, 7 and 14, respectively, diluted to 500. Mu.L with water, and then its fluorescence spectrum at 336nm wavelength excitation was measured with a fluorescence spectrophotometer.
Results:
from FIG. 1, it can be seen that Q5Y, Q6TY and Q7GY can form nanospheres with particle diameters smaller than 100nm, uniform sizes and regular shapes after pyrene is loaded.
As can be seen from FIG. 2, the fluorescence spectrum of the suspension obtained by loading Q5Y with pyrene, whose fluorescence at 480nm from pyrene nanoparticles remained substantially unchanged for 14 days, shows that the nanoparticle suspension formed by loading Q5Y with pyrene remained stable and uniform over a longer period of time.
The results of example 1 show that: Q5Y, Q6TY and Q7GY can load indissolvable model hydrophobic compounds pyrene to form nanospheres with uniform size, so that stable emulsion can be formed at the concentration of up to 2mg/mL, and the short peptides can be used for effectively loading the hydrophobic compounds.
Example 2: loading of the short peptides with the model hydrophobic Compound pyrene
Short peptide Ac-Ala-Ala-Ala-Tyr-NH 2 Abbreviated as A5Y, ac represents acetyl, SEQ ID NO.4 in the amino acid sequence Listing, and was delegated to chemical synthesis by Shandong Haibotai Biotechnology Co.
Pyrene was purchased from Sigma-Aldrich.
A5Y was dissolved in water according to its maximum solubility (about 0.5 mM) and sonicated for 5min. 20mg of pyrene is added into 10mL of short peptide mother liquor, and the mixture is placed at room temperature and magnetically stirred at 2000rpm/min for 4 hours, and then is subjected to ultrasonic treatment for 30 minutes to form milky suspension, and the milky suspension is placed at 4 ℃ for storage.
Morphological features were observed by high resolution transmission electron microscopy. After diluting the above suspension with water 5 times, 10. Mu.L of the sample solution was applied to a 400 mesh copper wire for 5 minutes, and then blotted with a piece of filter paper. Then, 10. Mu.L of 2% phosphotungstic acid was added thereto for dyeing for 3min. The final staining solution was blotted with filter paper and dried. And then imaging by adopting a transmission electron microscope.
The suspension of A5Y-loaded pyrene described above was left to stand at room temperature, 50. Mu.L of the suspension was taken out from the top layer on days 0, 7 and 14, respectively, diluted to 500. Mu.L with water, and then its fluorescence spectrum at 336nm wavelength excitation was measured with a fluorescence spectrophotometer.
Results:
as can be seen from FIG. 3, the particle size of the particles formed after A5Y is loaded with pyrene is larger than 100nm, and the particles are uneven in size and irregular in shape.
As can be seen from FIG. 4, the fluorescence spectrum of the suspension obtained by A5Y-loading pyrene, whose fluorescence peak at 480nm from pyrene nanoparticles was rapidly decreased, shows that the suspension formed by A5Y-loading pyrene was not very stable, and precipitation rapidly occurred during the standing process.
The results of example 2 show that: although the A5Y short peptide mainly composed of typical hydrophobic amino acids can disperse pyrene which is a model hydrophobic compound to form nano-scale particles, the drug carrying capacity is poor due to the limited solubility of the short peptide. The formed drug particles are larger, uneven in size and irregular in shape, so that the formed emulsion is extremely unstable in character and is precipitated quickly. The above results demonstrate that short peptides composed of typical hydrophobic amino acids do not load hydrophobic drugs to form good formulations compared to the materials of the present invention.
Example 3: loading of paclitaxel with short peptides
Materials: Q5Y entrusts the chemical synthesis of Shandong Botai Biotechnology Co., ltd; paclitaxel was purchased from calico biotechnology limited; the absolute ethyl alcohol is purchased in a chemical reagent factory of the Chemielong of the City department.
Preparing a short peptide mother solution: Q5Y was dissolved in water at 1mM and sonicated for 5min.
Preparing paclitaxel mother liquor: paclitaxel powder was dissolved in absolute ethanol at 20 mg/mL.
10mL of short peptide mother liquor is placed under the condition of magnetic stirring at room temperature at 2000rpm/min, 500 mu L of taxol mother liquor is added into the short peptide mother liquor drop by a liquid transfer device (the dosage ratio of Q5Y to taxol is 1 mu mol:1 mg), after the addition is finished, the magnetic stirring is continued for 30min, the ultrasonic treatment is carried out for 10min, and the short peptide mother liquor is preserved at 4 ℃.
Example 4: loading of paclitaxel with short peptides
Q6TY entrusts the chemical synthesis of Shandong Botai Biotechnology Co., ltd; paclitaxel was purchased from calico biotechnology limited; the absolute ethyl alcohol is purchased in a chemical reagent factory of the Chemielong of the City department.
Preparing a short peptide mother solution: q6TY was dissolved in water at 1mM and sonicated for 15min.
Preparing paclitaxel mother liquor: paclitaxel powder was dissolved in absolute ethanol at 20 mg/mL.
500 mu L of taxol mother solution is placed under the condition of magnetic stirring at room temperature of 2000rpm/min, 10mL of short peptide mother solution is added into taxol mother solution drop by a liquid transfer device (the dosage ratio of Q6TY to taxol is 1 mu mol:1 mg), after the addition is finished, the magnetic stirring is continued for 30min, the ultrasonic treatment is carried out for 10min, and the solution is preserved at the temperature of 4 ℃.
Example 5: loading of paclitaxel with short peptides
Q7GY entrusts the chemical synthesis of Shanghai Biotechnology Co., ltd; paclitaxel was purchased from calico biotechnology limited; the absolute ethyl alcohol is purchased in a chemical reagent factory of the Chemielong of the City department.
Q7GY is dissolved in 2mL DMSO together with 5mM and 5mg/mL paclitaxel powder (the dosage ratio of Q7GY to paclitaxel is 1 mu mol:1 mg), and the solution is sonicated for 5min; removing the organic solvent by adopting a vacuum dryer, redissolving with 10mL of water, performing ultrasonic treatment for 10min, and storing at 4 ℃.
Example 6: inhibition of ovarian cancer cells by paclitaxel-oligopeptide formulations
Human ovarian cancer cells skov3 at 5×10 3 Cell/well density was seeded in 96-well plates and incubated for 24 hours. The supernatants were removed, paclitaxel-oligopeptide formulations (prepared as in example 3) were added at various concentrations, and paclitaxel (commercially available paclitaxel drug) at corresponding concentrations were used as controls, and after 48h incubation, cell viability was determined using cck-8 kit. OD values reflecting cell viability were measured using a microplate fluorometer at 490nm wavelength.
Results:
as shown in FIG. 5, the paclitaxel-short peptide preparation (Q5Y-PTX) of the present invention has more remarkable inhibitory effect on tumor cells than the paclitaxel preparation Taxol (Taxol) on the market at PTX concentration of 0.01. Mu.g/mL; with the increase of the concentration, the inhibition effect of the medicine tends to be saturated, but the preparation still has stronger inhibition effect on ovarian cancer cells.
Example 7: loading of doxorubicin with short peptides
Reagent: doxorubicin hydrochloride was purchased from calico biotechnology limited and triethylamine was purchased from the metropolitan chemical reagent plant.
Preparing a short peptide mother solution: Q5Y was dissolved in water at 1mM and sonicated for 5min.
Desalting doxorubicin hydrochloride: 10mg of doxorubicin hydrochloride powder was dissolved in 10ml of methanol, 10. Mu.L of triethylamine was added thereto, and the mixture was magnetically stirred overnight, and the organic solvent was evaporated under vacuum to obtain doxorubicin powder.
Preparing doxorubicin mother solution: doxorubicin powder was dissolved in absolute ethanol at 20 mg/mL.
10mL of short peptide mother liquor is placed under the condition of magnetic stirring at room temperature at 2000rpm/min, 500 mu L of doxorubicin mother liquor is added into the short peptide mother liquor drop by a liquid transfer device (the dosage ratio of Q5Y to doxorubicin is 1 mu mol:1 mg), after the addition is finished, the magnetic stirring is continued for 30min, the ultrasonic treatment is carried out for 10min, and the short peptide mother liquor is preserved at 4 ℃.
Example 8: loading of doxorubicin with short peptides
Reagent: doxorubicin hydrochloride was purchased from calico biotechnology limited and triethylamine was purchased from the metropolitan chemical reagent plant.
Preparing a short peptide mother solution: q6TY was dissolved in water at 1mM and sonicated for 5min.
Desalting doxorubicin hydrochloride: 10mg of doxorubicin hydrochloride powder was dissolved in 10ml of methanol, 10. Mu.L of triethylamine was added thereto, and the mixture was magnetically stirred overnight, and the organic solvent was evaporated under vacuum to obtain doxorubicin powder.
Preparing doxorubicin mother solution: doxorubicin powder was dissolved in absolute ethanol at 20 mg/mL.
500 mu L of doxorubicin mother solution is placed under the condition of magnetic stirring at room temperature of 2000rpm/min, 10mL of short peptide mother solution is added into the doxorubicin mother solution drop by a pipettor (the dosage ratio of Q6TY to doxorubicin is 1 mu mol:1 mg), after the addition is finished, the magnetic stirring is continued for 30min, the ultrasonic treatment is carried out for 10min, and the solution is preserved at 4 ℃.
Example 9: loading of doxorubicin with short peptides
Reagent: doxorubicin hydrochloride was purchased from calico biotechnology limited and triethylamine was purchased from the metropolitan chemical reagent plant.
Desalting doxorubicin hydrochloride: 10mg of doxorubicin hydrochloride powder was dissolved in 10ml of methanol, 10. Mu.L of triethylamine was added thereto, and the mixture was magnetically stirred overnight, and the organic solvent was evaporated under vacuum to obtain doxorubicin powder.
Q7GY is dissolved in 2mL DMSO according to 5mM and doxorubicin powder of 5mg/mL (namely, the dosage ratio of Q7GY to doxorubicin is 1 mu mol:1 mg), and the solution is sonicated for 5min; removing the organic solvent by adopting a vacuum dryer, redissolving with 10mL of water, performing ultrasonic treatment for 10min, and storing at 4 ℃.
Example 10: inhibition of ovarian cancer cells by doxorubicin-short peptide formulations
Human ovarian cancer cells skov3 at 5×10 3 Cell/well density was seeded in 96-well plates and incubated for 24 hours. The supernatant was removed, doxorubicin-short peptide preparations (prepared using the method of example 8) at various concentrations were added, and doxorubicin hydrochloride at corresponding concentrations were used as a control, and after incubation for 48 hours, the cell viability was determined using cck-8 kit. Reflecting the cell viabilityThe OD of (C) was measured at 490nm using a microplate fluorometer.
Results:
the comparison of the experimental group and the control group shows that the doxorubicin-short peptide preparation (Q6 TY-DOX) has remarkable inhibition effect on tumor cells, which is equivalent to that of the control group drug doxorubicin hydrochloride (figure 6).
Example 11: loading of etomidate with short peptides
Q7GY entrusts the chemical synthesis of Shanghai Biotechnology Co., ltd; etomidate was purchased from dalteparin biotechnology limited; the absolute ethyl alcohol is purchased in a chemical reagent factory of the Chemielong of the City department.
Preparing a short peptide mother solution: q7GY was dissolved in 0.9% physiological saline at 0.5mM, and sonicated for 10min after vortexing.
20mg of etomidate is weighed, added into 10mL of short peptide mother liquor (the ratio of Q7GY to etomidate dosage is 5 mu mol:20 mg), vortexed and then subjected to ultrasonic treatment for 20min, and then placed under the condition of magnetic stirring at room temperature at 2000rpm/min, stirred for 40min and stored at room temperature.
Example 12: anesthetic effect of single injection of etomidate-oligopeptide preparation into tail vein of rat
Healthy adult male SD rats (body weight: 295.+ -.14 g) were used. Rats were placed in a holder, tail exposed, lateral tail vein found, and left needle cannulated for administration after alcohol swabbing (etomidate-oligopeptide formulation was prepared using the procedure of example 11). And 0.6mL of medicine is uniformly administered at a constant administration speed of 0.1mL/s, and after the administration is finished, 0.05mL of air is pushed to ensure that the medicine completely enters the tail vein and then the indwelling needle is pulled out, and the cotton swab presses for hemostasis. Rats were quickly removed and placed in empty cages, and the rat responses were observed for sedation scoring and adverse effects were recorded. Sedation score (Psychopharmacology 1996, 125:105-112): the tension of the limb muscles is normal, the autonomous activity can be kept, and the response sensitivity is 0 minutes; apparent thigmotaxis (rats tend to stay in a position near the cage rim) for 1 minute; withdrawal imbalance for 2 minutes; the forelimbs are erected to be less than 60 degrees, and ataxia is 3 minutes; prone, unable to stand, can only lean on abdomen to support 4 minutes; the specular reflection disappeared for 5 minutes. Observation of disappearance of the specular reflection (Anesthesiology 2000,93 (3): 837-843): the specular reflection disappears and continues for more than 30 seconds as "+", otherwise as "-".
Starting from a dose of 1mg/kg, a climbing experiment was performed to find out the dose of "+" and "-" respectively, as ED 50 (half of the effective amount, the amount that causes 50% of the maximum response intensity). Sequential determination of ED 50 Starting from the low dose, the sedative effect of the rats was observed, with the next dose decreasing (r=1.5, equal ratio) if "-", and with the next dose increasing equal ratio if "+"; from "-" to "+" or "+" to "-" is a crossover, 5 crossover experiments were terminated. By the dixon-mood method (ED 50 =lg-1 (Σc/Σt) to calculate ED of the drug in rat body 50 . And 95% confidence interval 95% ci=lg-1 (lgED) was calculated 50 ±1.96slgED 50 ),slgED 50 ={[ΣM-(ΣC)2/Σt]/(Σt·(Σt-1)}1/2。
Based on measured ED 50 A single tail vein injection of 2ED was performed on rats according to the above administration method 50 Drug, the sedative effect of rats was observed.
Results:
by comparison with the clinically used etomidate fat emulsion formulation (felide), it can be seen that the etomidate-short peptide formulation was comparable to the etomidate commercial formulation (felide) in anesthetic effect, and no significant adverse reactions occurred (table 1).
TABLE 1 comparison of Etomidate-short peptide formulations and Etomidate (Furling) efficacy
Example 13: loading of Propofol with short peptides
Q7GY entrusts the chemical synthesis of Shanghai Biotechnology Co., ltd; propofol was purchased from Sigma-Aldrich.
Preparing a short peptide mother solution: q7GY was dissolved in 0.9% physiological saline at 1mM, and sonicated for 10min after vortexing.
100mg of propofol is taken and added into 9.9mL of short peptide mother liquor in a dropwise manner, the mixture is subjected to ultrasonic treatment for 20min after vortex, and then the mixture is placed under the condition of magnetic stirring at room temperature of 2000rpm/min, stirred for 40min and stored at room temperature.
Example 14: anesthetic effect of single injection of propofol-short peptide formulation into rat tail vein
Healthy adult male SD rats (body weight: 295.+ -.14 g) were used. Rats were placed in a holder, tail exposed, lateral tail vein found, and left for needle catheterization after alcohol swabbing (propofol-short peptide formulation was prepared using the procedure of example 13). And 0.6mL of medicine is uniformly administered at a constant administration speed of 0.1mL/s, and after the administration is finished, 0.05mL of air is pushed to ensure that the medicine completely enters the tail vein and then the indwelling needle is pulled out, and the cotton swab presses for hemostasis. Rats were quickly removed and placed in empty cages, and rat responses were observed for sedation scoring and adverse effects were recorded (CFDA "guidelines for drug word dosing toxicity" (solicitation opinion manuscript 2013-05-26)). Sedation score (Psychopharmacology 1996, 125:105-112): the tension of the limb muscles is normal, the autonomous activity can be kept, and the response sensitivity is 0 minutes; apparent thigmotaxis (rats tend to stay in a position near the cage rim) for 1 minute; withdrawal imbalance for 2 minutes; the forelimbs are erected to be less than 60 degrees, and ataxia is 3 minutes; prone, unable to stand, can only lean on abdomen to support 4 minutes; the specular reflection disappeared for 5 minutes. Observation of disappearance of the specular reflection (Anesthesiology 2000,93 (3): 837-843): the specular reflection disappears and continues for more than 30 seconds as "+", otherwise as "-".
Starting from a dose of 1mg/kg, a climbing experiment was performed to find out the dose of "+" and "-" respectively, as ED 50 Experimental dosing reference range. Sequential determination of ED 50 Starting from the low dose, the sedative effect of the rats was observed, with the next dose decreasing (r=1.5, equal ratio) if "-", and with the next dose increasing equal ratio if "+"; from "-" to "+" or "+" to "-" is a crossover, 5 crossover experiments were terminated. By the dixon-mood method (ED 50 =lg-1 (Σc/Σt) to calculate ED of the drug in rat body 50 . And 95% confidence interval 95% ci=lg-1 (lgED) was calculated 50 ±1.96slgED 50 ),slgED 50 ={[ΣM-(ΣC)2/Σt]/(Σt·(Σt-1)}1/2。
Results:
ED by comparison with clinically used Propofol fat emulsion formulations (Depu Li Ma) 50 It can be seen that the anesthetic effect of the propofol-short peptide formulation was slightly better than that of the clinically marketed propofol formulation (Depu Li Ma) (Table 2).
TABLE 2 Propofol-short peptide formulations and ED of Propofol (Depu Li Ma) 50 Comparison
Example 15: effect of short peptides on ovarian cancer cells
Human ovarian cancer cells skov3 at 5×10 3 Cell/well density was seeded in 96-well plates and incubated for 24 hours. The supernatant was removed, and after incubation for 48h, the cell viability was determined using the cck-8 reagent method with different concentrations of Q5Y, Q TY and Q7GY short peptides. OD values reflecting cell viability were measured using a microplate fluorometer at 490 nm.
From the results, it can be seen that the Q5Y, Q6TY and Q7GY short peptides do not significantly inhibit tumor cells, proving that they have no significant cytotoxicity (fig. 7).
Example 16: nanostructure characterization
The morphological characteristics of nanospheres formed by hydrophobic drugs such as paclitaxel, doxorubicin, etomidate, propofol and the like loaded on Q5Y, Q TY and Q7GY are observed through a high-resolution Transmission Electron Microscope (TEM).
10. Mu.L of the sample solution was applied to a 400 mesh copper mesh for 5min, and then blotted dry with a piece of filter paper. Then, 10. Mu.L of 2% phosphotungstic acid was added thereto for dyeing for 3min. The final staining solution was blotted with filter paper and dried. And then imaging by adopting a transmission electron microscope.
From fig. 8 to 11, it can be seen that the short peptide entrapped drug becomes a nano-scale spherical micelle.
The results show that: the number of hydrophobic amino acids can vary within a range without materially altering the ability of the short peptides to self-assemble into nanocarriers.
In addition, the polypeptide composed of the atypical hydrophobic amino acid Q as a main component and Q, Y, T according to different arrangements and combinations is supplemented with N, S, G and other uncharged amino acids and A, V, L, I, F and other traditional hydrophobic amino acids, and the self-assembly capacity of the short peptide of the invention to form the nano-carrier is not changed essentially. This will be exemplified below:
example 17: characterization of the self-Assembly Capacity of different short peptides
The short peptides Q5Y, Q TY2, Q4GY2, Q4NY2, Q5A2SG, N5Y, S5Y, D5Y, E5Y, K5Y, R Y and H5Y were submitted to chemical synthesis by the company Heterotai Biotechnology Co.
The sequences of Q3TY2, Q4GY2, Q4NY2, Q5A2SG, N5Y, S5Y, D5Y, E5Y, K5Y, R5Y and H5Y are shown in Table 3.
TABLE 3 amino acid sequences of Q3TY2, Q4GY2, Q4NY2 and Q5A2SG
Note that: ac represents acetyl.
Each of the short peptides was prepared as a 0.5mM aqueous solution, thioflavin T (ThT, available from Sigma-Aldrich Co.) was added to each 500. Mu.L of the short peptide solution at a final concentration of 10. Mu.M, and the fluorescence spectrum (excitation wavelength set at 450 nm) in the range of 460 to 600nm was measured by a fluorescence spectrophotometer to determine the presence or absence of self-assembly behavior similar to Q5Y.
Results:
as shown in FIG. 12, all of the short peptides containing Q, Y, T as the main component exhibited typical THT fluorescence peaks around 490nm, indicating that these short peptides all have similar self-assembly behavior as Q5Y. When all Q in Q5Y was replaced with N, S, D, E, K, R or H which is also a polar amino acid but does not contain a hydrophobic group, as shown in FIG. 13, none of the resulting N5Y, S5Y, D5Y, E5Y, K5Y, R Y and H5Y short peptides exhibited typical ThT fluorescence peaks, indicating that the short peptides composed of these polar amino acids which do not contain a hydrophobic group do not have self-assembly behavior.
Example 18: characterization of formation of nanospheres from different short peptide loading modes of hydrophobic drug pyrene
The Q3TY2, Q4GY2, Q4NY2 and Q5A2SG short peptides are entrusted to chemical synthesis by the company of Haibotai biotechnology; pyrene was purchased from Sigma-Aldrich.
Preparing a short peptide mother solution: each short peptide was dissolved in water at 1mM and sonicated for 5min.
And (3) placing 10mL of the short peptide mother solution under the condition of magnetic stirring at room temperature at 2000rpm/min, adding 20mg of pyrene into the short peptide mother solution, continuing magnetic stirring for 30min after the addition, performing ultrasonic treatment for 10min, and storing at 4 ℃.
Morphological features were observed by high resolution transmission electron microscopy. 10. Mu.L of the sample solution was applied to a 400 mesh copper mesh for 5min, and then blotted dry with a piece of filter paper. Then, 10. Mu.L of 2% phosphotungstic acid was added thereto for dyeing for 3min. The final staining solution was blotted with filter paper and dried. And then imaging by adopting a transmission electron microscope.
Results:
from fig. 14, it can be seen that each of the short peptides can encapsulate pyrene to form a nanosphere structure with uniform size.
The results of examples 17 to 18 show that the compounds of the general formula Q according to the invention m X n (m is 2-10, n is 0-5) the various short peptides of the structure have similar self-assembly behavior, and can wrap hydrophobic drugs to form a nanosphere structure. It can be reasonably deduced that: the general formula of the invention is shown as general formula Q m X n The compound formed by wrapping the hydrophobic drug with the short peptide with the structure in the formula (m is 2-10, n is 0-5) can generate similar drug effects as the compound formed by wrapping the hydrophobic drug with Q5Y.
In conclusion, the short peptide can effectively wrap the hydrophobic drugs to form nanospheres, and the drug effect of the short peptide is equivalent to that of a commercially available preparation taking lipid as a carrier. Meanwhile, the preparation developed by taking the short peptide of the invention as a carrier does not contain traditional lipid materials, so that side effects such as hyperlipidemia, lipid metabolism abnormality and the like caused by the lipid carrier can be avoided, and the preparation has better safety.
Claims (14)
1. A short peptide, characterized in that: the amino acid sequence of the short peptide is shown as SEQ ID NO. 1.
2. A chemically modified oligopeptide, characterized in that: the N end and/or the C end of the short peptide with the amino acid sequence shown as SEQ ID NO.1 are/is provided with chemical modification;
the N-terminal chemical modification is alternatively selected from: acetylation, biotin labeling, fluorescent group labeling;
the C-terminal chemical modification is alternatively selected from: amidation, fluorescent group labeling.
3. The chemically modified short peptide of claim 2, wherein: the N-terminal is chemically modified into a fluorescent group mark, and the fluorescent group mark is FAM, FITC or TAMRA;
the C-terminal chemical modification is a fluorescent group mark, and the fluorescent group mark is AMC, CMK and FMK.
4. The chemically modified short peptide of claim 2, wherein: the N-terminal is chemically modified into acetylation; and/or, the C-terminus is chemically modified to amidate.
5. Use of the short peptide of claim 1 or the chemically modified short peptide of any one of claims 2-4 in the preparation of a hydrophobic drug carrier.
6. Use according to claim 5, characterized in that: the carrier is a nanosphere formed by self-assembly of the short peptide.
7. Use according to claim 5 or 6, characterized in that:
the hydrophobic drug is paclitaxel, doxorubicin, curcumin, docetaxel, vincristine, camptothecin, hydroxycamptothecin, etoposide, retinoic acid, fluorouracil, methotrexate, teniposide, daunorubicin, aclacin, sorafenib, methylprednisone, minocycline, cisplatin, atorvastatin, simvastatin, lovastatin, amiodarone, carbamazepine, carvedilol, chlorpromazine, cisapride, chlorophenylsulfone, azithromycin, neomycin, amphotericin B, griseofulvin, celecoxib, raloxifene, flurbiprofen, indomethacin, ibuprofen, tamoxifen, simoxicillin, simvastatin, and other drugs diclofenac, naproxen, piroxicam, raltegravir, efavirenz, nelfinavir, atazanavir, ritonavir, sirolimus, busulfan, tacrolimus, ta Lin Luoer, terfenadine, estradiol, vitamin A, vitamin D, vitamin E, vitamin K, propofol, etomidate, perfluorocarbon, diazepam, prostadil, complex liposoluble vitamins, dexamethasone, flurbiprofen ester, clevidipine butyrate, brucea oil, cyclosporine, insulin, adefovir, chloroquine, hydroxychloroquine, fampicvir, lopinavir, ritonavir.
8. Use according to claim 7, characterized in that: the hydrophobic drug is paclitaxel, doxorubicin, etomidate or propofol.
9. A hydrophobic drug carrier, characterized by: the carrier is a nanosphere formed by self-assembly of the short peptide of claim 1 or the chemically modified short peptide of any one of claims 2-4.
10. A nanocarrier formulation characterized by: the preparation takes a hydrophobic drug as an active ingredient, and takes the nanospheres formed by self-assembly of the short peptide of claim 1 or the chemically modified short peptide of any one of claims 2-4 as a carrier.
11. The nanocarrier formulation of claim 10, wherein: the content ratio of short peptide to hydrophobic drug was 5. Mu. Mol: (1-100) mg.
12. The nanocarrier formulation of claim 10 or 11, wherein:
the hydrophobic drug is paclitaxel, doxorubicin, curcumin, docetaxel, vincristine, camptothecin, hydroxycamptothecin, etoposide, retinoic acid, fluorouracil, methotrexate, teniposide, daunorubicin, aclacinomycin, sorafenib, cisplatin, methylprednisone, minocycline, atorvastatin, simvastatin, lovastatin, amiodarone, carbamazepine, carvedilol, chlorpromazine, cisapride, chlorophenylsulfone, azithromycin, neomycin, amphotericin B, griseofulvin, celecoxib, raloxifene, flurbiprofen, indomethacin, ibuprofen, tamoxifen, pravastatin, and other drugs diclofenac, naproxen, piroxicam, raltefravir, efavirenz, nelfinavir, atazanavir, ritonavir, sirolimus, busulfan, tacrolimus, ta Lin Luoer, terfenadine, estradiol, vitamin A, vitamin D, vitamin E, vitamin K, propofol, etomidate, perfluorocarbon, diazepam, prostadil, complex liposoluble vitamins, dexamethasone, flurbiprofen ester, clevidipine butyrate, brucea oil, cyclosporine, insulin, adefovir, chloroquine, hydroxychloroquine, fampicvir, lopinavir, ritonavir.
13. The nanocarrier formulation of claim 12, wherein: the hydrophobic drug is paclitaxel, doxorubicin, etomidate or propofol.
14. The nanocarrier formulation of claim 13, wherein: the hydrophobic drug is paclitaxel, and the content ratio of the short peptide to the hydrophobic drug is 1 mu mol:1mg;
or the hydrophobic drug is doxorubicin, and the content ratio of the short peptide to the hydrophobic drug is 1 mu mol:1mg;
or the hydrophobic drug is etomidate, and the content ratio of the short peptide to the hydrophobic drug is 5 mu mol:20mg;
or the hydrophobic drug is propofol, and the content ratio of the short peptide to the hydrophobic drug is 9.9 mu mol/100 mg.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310186188.2A CN116333049B (en) | 2020-07-03 | 2020-07-03 | Atypical hydrophobic amino acid-based self-assembled short peptide and application thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010638716.XA CN111748016B (en) | 2020-07-03 | 2020-07-03 | Atypical hydrophobic amino acid-based self-assembled short peptide and application thereof |
CN202310186188.2A CN116333049B (en) | 2020-07-03 | 2020-07-03 | Atypical hydrophobic amino acid-based self-assembled short peptide and application thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010638716.XA Division CN111748016B (en) | 2020-07-03 | 2020-07-03 | Atypical hydrophobic amino acid-based self-assembled short peptide and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116333049A CN116333049A (en) | 2023-06-27 |
CN116333049B true CN116333049B (en) | 2024-03-29 |
Family
ID=72679315
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310186188.2A Active CN116333049B (en) | 2020-07-03 | 2020-07-03 | Atypical hydrophobic amino acid-based self-assembled short peptide and application thereof |
CN202310186187.8A Active CN116425833B (en) | 2020-07-03 | 2020-07-03 | Atypical hydrophobic amino acid-based self-assembled short peptide and application thereof |
CN202010638716.XA Active CN111748016B (en) | 2020-07-03 | 2020-07-03 | Atypical hydrophobic amino acid-based self-assembled short peptide and application thereof |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310186187.8A Active CN116425833B (en) | 2020-07-03 | 2020-07-03 | Atypical hydrophobic amino acid-based self-assembled short peptide and application thereof |
CN202010638716.XA Active CN111748016B (en) | 2020-07-03 | 2020-07-03 | Atypical hydrophobic amino acid-based self-assembled short peptide and application thereof |
Country Status (2)
Country | Link |
---|---|
CN (3) | CN116333049B (en) |
WO (1) | WO2022001701A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116333049B (en) * | 2020-07-03 | 2024-03-29 | 四川大学华西医院 | Atypical hydrophobic amino acid-based self-assembled short peptide and application thereof |
CN114805481B (en) * | 2022-02-28 | 2023-06-23 | 四川大学华西医院 | Short peptide and slow release preparation with long-acting analgesic or/and long-acting local anesthetic effect by taking short peptide as carrier material |
CN114796240B (en) * | 2022-06-08 | 2024-05-24 | 国家纳米科学中心 | Self-assembled chiral short peptide drug and preparation method and application thereof |
WO2024041532A1 (en) * | 2022-08-22 | 2024-02-29 | 赣州和美药业股份有限公司 | Tetravalent platinum-containing complex, prodrug, preparation method therefor, and use thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101337985A (en) * | 2008-08-28 | 2009-01-07 | 成都瑞恩生物技术有限公司 | Self-assembly short peptides constructed by D type amino acid, use for nano-biomedicine |
CN101939329A (en) * | 2007-08-30 | 2011-01-05 | 滑铁卢大学 | Amino acid pairing-based self assembling peptides and methods |
KR101581926B1 (en) * | 2014-09-23 | 2016-01-04 | 연세대학교 산학협력단 | self-assembly peptide nano-capsule and drug-delivery carrier comprising the same |
CN111233979A (en) * | 2020-02-19 | 2020-06-05 | 四川大学华西医院 | Gemini-type amphiphilic short peptide and application thereof as hydrophobic drug carrier |
WO2022001701A1 (en) * | 2020-07-03 | 2022-01-06 | 四川大学华西医院 | Self-assembled short peptide based on atypical hydrophobic amino acid and use thereof |
CN115947786A (en) * | 2023-01-30 | 2023-04-11 | 四川大学华西医院 | Self-assembled short peptide with crystallization inducing capability and long-acting local anesthesia and antitumor drug prepared from self-assembled short peptide |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2331743B1 (en) * | 2008-08-13 | 2013-07-10 | Dow Global Technologies LLC | Peptide-coated fibers |
US9849174B2 (en) * | 2009-11-20 | 2017-12-26 | The Board Of Regents Of The University Of Texas System | Methods and compositions related to immunogenic fibrils |
CN105708799A (en) * | 2016-01-27 | 2016-06-29 | 金银秀 | Nano-structural lipid carrier pharmaceutical composition and preparation method thereof |
CN107375238B (en) * | 2016-05-16 | 2022-04-01 | 刘东飞 | Ultrahigh drug-loading nanoparticle and preparation method thereof |
US11433143B2 (en) * | 2017-05-18 | 2022-09-06 | The Regents Of The University Of California | Nano-enabled immunotherapy in cancer |
-
2020
- 2020-07-03 CN CN202310186188.2A patent/CN116333049B/en active Active
- 2020-07-03 CN CN202310186187.8A patent/CN116425833B/en active Active
- 2020-07-03 CN CN202010638716.XA patent/CN111748016B/en active Active
-
2021
- 2021-06-18 WO PCT/CN2021/100932 patent/WO2022001701A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101939329A (en) * | 2007-08-30 | 2011-01-05 | 滑铁卢大学 | Amino acid pairing-based self assembling peptides and methods |
CN101337985A (en) * | 2008-08-28 | 2009-01-07 | 成都瑞恩生物技术有限公司 | Self-assembly short peptides constructed by D type amino acid, use for nano-biomedicine |
KR101581926B1 (en) * | 2014-09-23 | 2016-01-04 | 연세대학교 산학협력단 | self-assembly peptide nano-capsule and drug-delivery carrier comprising the same |
CN111233979A (en) * | 2020-02-19 | 2020-06-05 | 四川大学华西医院 | Gemini-type amphiphilic short peptide and application thereof as hydrophobic drug carrier |
WO2022001701A1 (en) * | 2020-07-03 | 2022-01-06 | 四川大学华西医院 | Self-assembled short peptide based on atypical hydrophobic amino acid and use thereof |
CN115947786A (en) * | 2023-01-30 | 2023-04-11 | 四川大学华西医院 | Self-assembled short peptide with crystallization inducing capability and long-acting local anesthesia and antitumor drug prepared from self-assembled short peptide |
Non-Patent Citations (3)
Title |
---|
Nanoribbons self-assembled from short peptides demonstrate the formation of polar zippers between β-sheets;Meng Wang;《NATURE COMMUNICATIONS》;20181231;第9卷;第1-11页 * |
Self-Assembling Peptides and Their Application in the Treatment of Diseases;Sungeun Lee;《International Journal o f Molecular Sciences》;20191231;第20卷;第1-22页 * |
多肽自组装的结构调控及其药物和基因载体应用;曹美文;《中国化学会第17 届胶体与界面化学学术会议论文(摘要)》;20190728;摘要 * |
Also Published As
Publication number | Publication date |
---|---|
WO2022001701A1 (en) | 2022-01-06 |
CN116333049A (en) | 2023-06-27 |
CN111748016A (en) | 2020-10-09 |
CN116425833B (en) | 2024-03-29 |
CN111748016B (en) | 2023-05-02 |
CN116425833A (en) | 2023-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN116333049B (en) | Atypical hydrophobic amino acid-based self-assembled short peptide and application thereof | |
Zhang et al. | Development of curcumin-loaded zein nanoparticles for transport across the blood–brain barrier and inhibition of glioblastoma cell growth | |
Zhang et al. | Ethyl oleate-containing nanostructured lipid carriers improve oral bioavailability of trans-ferulic acid ascompared with conventional solid lipid nanoparticles | |
Doktorovova et al. | Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers–a systematic review of in vitro data | |
Yang et al. | A pH-responsive drug nanovehicle constructed by reversible attachment of cholesterol to PEGylated poly (l-lysine) via catechol–boronic acid ester formation | |
Kanwal et al. | Design of absorption enhancer containing self-nanoemulsifying drug delivery system (SNEDDS) for curcumin improved anti-cancer activity and oral bioavailability | |
Omolo et al. | Pegylated oleic acid: A promising amphiphilic polymer for nano-antibiotic delivery | |
CN105853403B (en) | A kind of paclitaxel palmitate liposome and preparation method thereof | |
Gonçalves et al. | Self-assembled dextrin nanogel as curcumin delivery system | |
Zhu et al. | Nanodiamond mediated co-delivery of doxorubicin and malaridine to maximize synergistic anti-tumor effects on multi-drug resistant MCF-7/ADR cells | |
Mhule et al. | Synthesis of an oleic acid based pH-responsive lipid and its application in nanodelivery of vancomycin | |
Jalali et al. | Surface modification of poly (lactide-co-glycolide) nanoparticles by d-α-tocopheryl polyethylene glycol 1000 succinate as potential carrier for the delivery of drugs to the brain | |
JP2016503012A (en) | Formulations and carrier systems containing compound interaction domains | |
Peng et al. | Facile design of gemini surfactant-like peptide for hydrophobic drug delivery and antimicrobial activity | |
Lin et al. | Honokiol/magnolol-loaded self-assembling lecithin-based mixed polymeric micelles (lb MPMs) for improving solubility to enhance oral bioavailability | |
Tannous et al. | Drug-encapsulated cyclodextrin nanosponges | |
CN114712514B (en) | Nanometer medicinal preparation for reducing blood fat locally and systemically, and its application | |
Shankar et al. | Potential applications of nanomedicine for treating Parkinson's disease | |
Murugesan et al. | Niosomal formulation of Quercetin and Resveratrol and in-vitro release studies | |
Yi et al. | Preparation, characterization, and in vitro pharmacodynamics and pharmacokinetics evaluation of PEGylated urolithin A liposomes | |
Li et al. | Size-transformable gelatin/nanochitosan/doxorubicin nanoparticles with sequentially triggered drug release for anticancer therapy | |
Li et al. | Nose-to-brain delivery of self-assembled curcumin-lactoferrin nanoparticles: Characterization, neuroprotective effect and in vivo pharmacokinetic study | |
CN111233979A (en) | Gemini-type amphiphilic short peptide and application thereof as hydrophobic drug carrier | |
Asghari et al. | PEGylated cationic nano-niosomes formulation containing herbal medicine curcumin for drug delivery to MCF-7 breast cancer cells | |
Sharifyrad et al. | The efficacy and neuroprotective effects of edaravone-loaded mPEG-b-PLGA polymeric nanoparticles on human neuroblastoma SH-SY5Y cell line as in vitro model of ischemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |